Syngene International Limited has announced its audited consolidated financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue from operations of Rs. 10,365 million for the quarter, representing a 13.02% increase from the previous quarter’s Rs. 9,171 million. Compared to the same quarter last year, revenue grew by 1.82% from Rs. 10,180 million. Net profit for the quarter stood at Rs. 1,479 million, a significant jump from Rs. 150 million in the preceding quarter, though it saw a 19.31% decline year-on-year from Rs. 1,833 million. The Board of Directors also recommended a final dividend of Re. 1.25 per equity share for the financial year 2025-26.

Syngene International Limited, a subsidiary of Biocon Limited, is a leading integrated contract research, development, and manufacturing organization (CRMO) based in India. The company provides a wide range of services to global pharmaceutical, biotechnology, and agrochemical companies, spanning discovery chemistry, biology, and large-scale manufacturing. Syngene operates state-of-the-art facilities in Bengaluru and Mangaluru and has a growing global footprint, including a biologics manufacturing site in the USA. The company is known for its long-term strategic partnerships and its focus on innovation and quality in the scientific services domain.